

| | | | |
|--|--|--------------|--------------------|
| Client: ASPIRE REJUVENATION AND A | | Patient: | |
| Phys: | | Phone: () - | DOB. |
| | | Age:51 Sex:M | |
| | | Fasting: Y | |
| | | Address 1: | |
| | | Address 2: | |
| | | City: | State: Zip: Page:1 |

| | | | |
|--------------------|-------------|----------------------|----------------------|
| Acc# | Coll. Date: | Recv. Date: 05/28/22 | Print Date: 06/02/22 |
| Chart# | Coll. Time: | Recv. Time:01:58 PM | Print Time: 12:02 |
| First reported on: | | Final report date: | 06/01/22 |

Report Status: FINAL

| Test Name | Results | Reference Range | Units |
|---|---------|-----------------|---------------|
| *****OUT OF RANGE SUMMARY***** | | | |
| Glucose | 109 H | 65 - 99 | mg/dL *I |
| Cholesterol, Total | 212 H | 100 - 199 | mg/dL *I |
| LDL Chol Calc (NIH) | 144 H | 0 - 99 | mg/dL *I |
| Testosterone | 235 L | 264 - 916 | ng/dL *I |
| Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. | | | |
| ***** | | | |
| reported: 05/29/22 08:06 Comp. Metabolic Panel (14) | | | |
| Glucose | 109 H | 65 - 99 | mg/dL *I |
| BUN | 10 | 6 - 24 | mg/dL *I |
| Creatinine | 0.86 | 0.76 - 1.27 | mg/dL *I |
| eGFR | 105 | >59 | mL/min/1.7 *I |
| BUN/Creatinine Ratio | 12 | 9 - 20 | *I |
| Sodium | 140 | 134 - 144 | mmol/L *I |
| Potassium | 4.8 | 3.5 - 5.2 | mmol/L *I |
| Chloride | 99 | 96 - 106 | mmol/L *I |
| Carbon Dioxide, Total | 21 | 20 - 29 | mmol/L *I |
| Calcium | 10.1 | 8.7 - 10.2 | mg/dL *I |
| Protein, Total | 7.2 | 6.0 - 8.5 | g/dL *I |
| Albumin | 4.8 | 3.8 - 4.9 | g/dL *I |
| Globulin, Total | 2.4 | 1.5 - 4.5 | g/dL *I |
| A/G Ratio | 2.0 | 1.2 - 2.2 | *I |
| Bilirubin, Total | <0.2 | 0.0 - 1.2 | mg/dL *I |
| Alkaline Phosphatase | 70 | 44 - 121 | IU/L *I |
| AST (SGOT) | 25 | 0 - 40 | IU/L *I |
| ALT (SGPT) | 29 | 0 - 44 | IU/L *I |
| reported: 05/29/22 08:06 Lipid Panel | | | |
| Cholesterol, Total | 212 H | 100 - 199 | mg/dL *I |
| Triglycerides | 91 | 0 - 149 | mg/dL *I |

(Continued on Next Page)

Client: **ASPIRE REJUVENATION AND A**

Patient:

Phone:

DOB:

Age: 51 Sex: M

Address 1:

Fasting: Y

Address 2:

Phys:

City:

State:

Zip:

Page: 2

Acc#

Coll. Date:

Recv. Date: 05/28/22

Print Date: 06/02/22

Chart#

Coll. Time:

Recv. Time: 01:58 PM

Print Time: 12:02

First reported on:

Final report date:

06/01/22

Report Status: FINAL
Test Name
Results
Reference Range
Units

***** (Continued)

| | | | | |
|----------------------|--------------|--------|-------|----|
| HDL Cholesterol | 52 | >39 | mg/dL | *I |
| VLDL Cholesterol Cal | 16 | 5 - 40 | mg/dL | *I |
| LDL Chol Calc (NIH) | 144 H | 0 - 99 | mg/dL | *I |

reported: 05/29/22 08:06

CBC, Platelet, No Differential

| | | | | |
|------------|------|-------------|----------|----|
| WBC | 9.2 | 3.4 - 10.8 | x10E3/uL | *I |
| RBC | 4.89 | 4.14 - 5.80 | x10E6/uL | *I |
| Hemoglobin | 15.5 | 13.0 - 17.7 | g/dL | *I |
| Hematocrit | 46.8 | 37.5 - 51.0 | % | *I |
| MCV | 96 | 79 - 97 | fL | *I |
| MCH | 31.7 | 26.6 - 33.0 | pg | *I |
| MCHC | 33.1 | 31.5 - 35.7 | g/dL | *I |
| RDW | 12.8 | 11.6 - 15.4 | % | *I |
| Platelets | 258 | 150 - 450 | x10E3/uL | *I |

reported: 05/29/22 08:06

| | | | | |
|----------------------|-----|-----------|-------|----|
| Prostate Specific Ag | 0.6 | 0.0 - 4.0 | ng/mL | *I |
|----------------------|-----|-----------|-------|----|

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

reported: 05/29/22 08:06

| | | | | |
|-----------------------------|-----|-----------|-------|----|
| Triiodothyronine (T3), Free | 3.0 | 2.0 - 4.4 | pg/mL | *I |
|-----------------------------|-----|-----------|-------|----|

reported: 05/29/22 08:06

Thyroxine (T4) Free, Direct

| | | | | |
|-----------------|-------|---------------|--------|----|
| T4,Free(Direct) | 1.15 | 0.82 - 1.77 | ng/dL | *I |
| TSH | 1.860 | 0.450 - 4.500 | uIU/mL | *I |
| Estradiol | 14.1 | 7.6 - 42.6 | pg/mL | *I |

Roche ECLIA methodology

(Continued on Next Page)

Client: **ASPIRE REJUVENATION AND A**

Patient:

Phone: () -

DOB. (

Age: 51 Sex: M

Fasting: Y

Address 1:

Address 2:

City:

State:

Zip:

Page: 3

Phys:

Acc#

Coll. Date:

Recv. Date: 05/28/22

Print Date: 06/02/22

Chart#

Coll. Time:

Recv. Time: 01:58 PM

Print Time: 12:02

First reported on:

Final report date:

06/01/22

Report Status: FINAL

| Test Name | Results | Reference Range | Units |
|---|---------|-----------------|-----------|
| ***** (Continued) | | | |
| Testosterone Free, Profile I | | | |
| Testosterone | 235 L | 264 - 916 | ng/dL *I |
| Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. | | | |
| Sex Horm Binding Glob, Serum | 32.8 | 19.3 - 76.4 | nmol/L *I |
| Testost., Free, Calc | 43.1 | 35.8 - 168.2 | pg/mL *I |
| IGF-1 | | | |
| Insulin-Like Growth Factor I | 120 | 74 - 255 | ng/mL *I |

COMMENTS:

Fasting,

END OF REPORT

*I) Unless otherwise noted, Tests Performed at :

LABCORP, 5610 WEST LA SALLE STREET, TAMPA, FL 33607